Clinical trials: Pancreatic Metastasis
Pancreatic Cancer
Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma
The purpose of this study is to define th Maximum Tolerated Dose (MTD) and the recommended dose (RD) of ZD6474 in combination with a fixed standard dose of gemcitabine and capecitabine
- Trial name
- NCT00681798
- Testing
- Vandetanib
- Where
- 2 sites in Switzerland
- Volunteers
- 8 people
- Sponsor
- Sanofi
Pancreatic Cancer
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of tadalafil, pembrolizumab, ipilimumab, and CRS-207 in subjects with metastatic pancreatic adenocarcinoma who have progressed after at least 1 prior…
- Trial name
- NCT05014776
- Testing
- Tadalafil, Pembrolizumab, Ipilimumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602082
- Testing
- capecitabine, cisplatin, streptozocin
- Where
- 17 sites in United Kingdom
- Volunteers
- 84 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Pancreatic Cancer
Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer
Erlotinib is an orally available, reversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR). Association of chemoresistance with the activity of certain tyrosine kinases (e.g.
- Trial name
- GEMOX-T (NCT01505413)
- Testing
- Erlotinib, Gemcitabine, Oxaliplatin
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Soonchunhyang University Hospital
Cancer Metastatic to the Liver, Hepatocellular Carcinoma
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not…
- Conditions
- Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma
- Trial name
- NCT00986661
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 5 sites in United States
- Volunteers
- 78 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Pancreas Cancer
Study of Pemetrexed for Second-Line Pancreas Cancer
This study is for patients with pancreatic cancer that has grown and/or spread after having previously received the standard chemotherapy drug called gemcitabine. In this study a drug called pemetrexed is being tested.
- Trial name
- NCT00864513
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Georgetown University
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic…
- Trial name
- MAESTRO (NCT01746979)
- Testing
- TH-302, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 693 people
- Sponsor
- ImmunoGenesis
Pancreas Cancer, Localized Pancreas Cancer
Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer
A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)
- Conditions
- Pancreas Cancer, Localized Pancreas Cancer, Non-metastatic Pancreas Cancer
- Trial name
- NCT01771146
- Testing
- FOLFIRINOX Regimen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor Research Institute
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
This is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal…
- Trial name
- NCT07076212
- Testing
- Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Medical University of South Carolina
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT07148128
- Testing
- WEF-001
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Auricula Biosciences Inc.
Disorder of Upper Gastrointestinal Tract, Pancreatic Nodule
Tissue Characterisation by Endoscopic GI-elastography
In this single centre study we study the use of endoscopic ultrasonography (EUS) combined with elastography in order to separate malignant tissue from benign tissue in and adjacent to the upper gastrointestinal tract.
- Conditions
- Disorder of Upper Gastrointestinal Tract, Pancreatic Nodule, Secondary and Unspecified Malignant Neoplasm of Retroperitoneal Lymph Nodes, Secondary Malignant Neoplasm of Lymph Node
- Trial name
- NCT01360411
- Where
- Norway
- Volunteers
- 137 people
- Sponsor
- Haukeland University Hospital
Neuroendocrine Carcinoma, Grade 3
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Phase II study of avelumab in metastatic gastronetro-pancreatic (GEP) neuroendocrine carcinoma (NEC, WHO grade 3) as second-line treatment after failing to etoposide+cisplatin: integration of genomic analysis to identify…
- Trial name
- MS100070-0177 (NCT03147404)
- Testing
- Avelumab
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Samsung Medical Center
Recurrent Adenocarcinoma of the Pancreas, Metastatic Adenocarcinoma of the Pancreas
Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas
Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas.
- Trial name
- NCT02739633
- Testing
- Genexol-PM, Gemcitabine
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite…
- Conditions
- Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
- Trial name
- Pan-MSI-ACSE (NCT06333314)
- Testing
- Dostarlimab, Chemotherapy
- Where
- 22 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER
Merkel Cell Carcinoma, Islet Cell Carcinoma
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Merkel Cell Carcinoma, Islet Cell Carcinoma, Neuroendocrine Carcinoma, Pituitary Tumor
- Trial name
- NCT00003514
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.
- Trial name
- NCT02754726
- Testing
- Nivolumab, Albumin-bound paclitaxel, Paricalcitol
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- HonorHealth Research Institute
Metastatic Pancreatic Cancer
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
This is a multicenter, open-label, phase II study to explore the efficacy, safety/tolerability and pharmacokinetics (PK) of GFH375 in in Patients with Previously Treated KRAS G12D Mutant Metastatic Pancreatic Cancer.
- Trial name
- NCT07026916
- Testing
- GFH375
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Pancreatic Cancer
Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer
Depression and anxiety accompany with advanced cancer. The effect of anti-anxiety depression has not evaluated in special cancers. Mirtazapine is a drug anti-anxiety depression and has a high risk increase weight.
- Trial name
- NCT01598584
- Testing
- Mirtazapine plus gemcitabine
- Where
- China
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer, Metastatic Pancreatic Cancer
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
This study will compare the anti-tumor efficacy of apricoxib and gemcitabine/erlotinib with placebo and gemcitabine/erlotinib in patients with advanced pancreatic cancer.
- Trial name
- NCT00709826
- Testing
- gemcitabine, Erlotinib, apricoxib
- Where
- 39 sites in United States
- Volunteers
- 109 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.